156 related articles for article (PubMed ID: 27958379)
1. A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia.
Mannarino L; Paracchini L; Craparotta I; Romano M; Marchini S; Gatta R; Erba E; Clivio L; Romualdi C; D'Incalci M; Beltrame L; Pattini L
Pharmacogenomics J; 2018 Jan; 18(1):56-63. PubMed ID: 27958379
[TBL] [Abstract][Full Text] [Related]
2. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
[TBL] [Abstract][Full Text] [Related]
3. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
Uboldi S; Craparotta I; Colella G; Ronchetti E; Beltrame L; Vicario S; Marchini S; Panini N; Dagrada G; Bozzi F; Pilotti S; Galmarini CM; D'Incalci M; Gatta R
BMC Cancer; 2017 Feb; 17(1):107. PubMed ID: 28166781
[TBL] [Abstract][Full Text] [Related]
5. In-Silico Identification of Novel Pharmacological Synergisms: The Trabectedin Case.
Mannarino L; Ravasio N; D'Incalci M; Marchini S; Masseroli M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396735
[TBL] [Abstract][Full Text] [Related]
6. Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.
Cucè M; Gallo Cantafio ME; Siciliano MA; Riillo C; Caracciolo D; Scionti F; Staropoli N; Zuccalà V; Maltese L; Di Vito A; Grillone K; Barbieri V; Arbitrio M; Di Martino MT; Rossi M; Amodio N; Tagliaferri P; Tassone P; Botta C
J Hematol Oncol; 2019 Mar; 12(1):32. PubMed ID: 30898137
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response.
Souid S; Aissaoui D; Srairi-Abid N; Essafi-Benkhadir K
Curr Drug Targets; 2020; 21(10):996-1007. PubMed ID: 31994460
[TBL] [Abstract][Full Text] [Related]
8. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
9. Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ray-Coquard I
Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R; Marrari A; Santoro A
Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
14. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
15. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
[TBL] [Abstract][Full Text] [Related]
17. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
[TBL] [Abstract][Full Text] [Related]
18. Trabectedin mechanism of action: what's new?
D'Incalci M
Future Oncol; 2013 Dec; 9(12 Suppl):5-10. PubMed ID: 24195524
[TBL] [Abstract][Full Text] [Related]
19. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin has promising antineoplastic activity in high-grade meningioma.
Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
